News
MRNA
47.44
-8.04%
-4.15
Moderna Inc. Stock Sheds 8.0%, Underperforms Peers
Dow Jones · 4h ago
U.S. State Dept Announces Nearly $38M In Additional Funding Toward The Department's Ongoing Ebola Response Efforts
Benzinga · 6h ago
Moderna Inc. Stock Climbs 5.2%, Outperforms Peers
Dow Jones · 1d ago
Acting FDA head vows to block political interference, Endpoint News says
TipRanks · 1d ago
Moderna’s CMV Vaccine Study Update: What mRNA‑1647 Progress Means for MRNA Investors
TipRanks · 1d ago
Three studies used to justify U.S. vaccine policy under RFK Jr. face scrutiny: Guardian
Seeking Alpha · 1d ago
Why Is Moderna (MRNA) Stock Rocketing Higher Today
Barchart · 1d ago
A Look At Moderna (MRNA) Valuation After Positive Five Year Melanoma Vaccine Trial Data
Simply Wall St · 1d ago
Moderna Stock: Is MRNA Outperforming the Health Care Sector?
Barchart · 1d ago
Moderna Inc. Stock Climbs 7.5%, Outperforms Peers
Dow Jones · 2d ago
Barclays Sticks to Their Hold Rating for Moderna (MRNA)
TipRanks · 2d ago
Meet the Biotech Stock That's Trouncing Lilly, Merck, and Pfizer in 2026
NASDAQ · 2d ago
Health Rounds: Radiation-emitting implant improves outcomes after brain cancer surgery
Reuters · 3d ago
Analysts Offer Insights on Healthcare Companies: Moderna (MRNA) and Mediwound (MDWD)
TipRanks · 3d ago
Analysts Offer Insights on Healthcare Companies: Labcorp Holdings (LH), Moderna (MRNA) and Celcuity (CELC)
TipRanks · 3d ago
FDA issues draft guidance to help accelerated cell, gene therapies for patients
TipRanks · 3d ago
Analysts Conflicted on These Healthcare Names: BeOne Medicines (ONC), Moderna (MRNA) and Danaher (DHR)
TipRanks · 3d ago
Moderna to present at Goldman Sachs Global Healthcare Conference
PUBT · 3d ago
Moderna posts oncology event presentation on intismeran cancer vaccine program
PUBT · 4d ago
Moderna, Merck release promising data on mRNA cancer vaccine
Seeking Alpha · 4d ago
More
Webull provides a variety of real-time MRNA stock news. You can receive the latest news about Moderna through multiple platforms. This information may help you make smarter investment decisions.
About MRNA
Moderna, Inc. is a biotechnology company advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is engaged in developing medicines across infectious disease vaccines, oncology therapeutics and rare disease therapeutics. Its platform incorporates advances across three components, mRNA, delivery, and the manufacturing process, to advance its medicines. Its products are Spikevax and mNEXSPIKE (its COVID vaccines), and mRESVIA (its vaccine against respiratory syncytial virus (RSV)). It also has a diverse development pipeline that consists of 35 therapeutic and vaccine programs, six of which are in late-stage development. It has regulatory filings under review for its seasonal flu+COVID vaccine (mRNA-1083) in Europe and Canada and for its seasonal flu vaccine (mRNA-1010) in the United States, Europe, Canada and Australia. Its rare disease programs are Propionic acidemia (mRNA-3927); Methylmalonic acidemia (mRNA-3705), and Cystic Fibrosis (mRNA-3692/VX-522).